Acute myeloid leukemia (AML) is a cancer of the blood cells that mostly strikes older adults. According to the American Cancer Society, nearly 20,000 Americans will be diagnosed with the disease this year. Over 10,000 will die of it.
An experimental therapy that revs up the immune system’s cancer-fighting ability may help treat some leukemia patients who face a grim prognosis, a small study suggests.
The treatment involves infusions of “natural killer” (NK) cells taken from a healthy donor and chemically “trained” to go after tumor cells.
Researchers found that of nine patients with AML who received the
